IART, US4579852082

Integra LifeSciences stock cuts guidance after Cincinnati flooding

Published on 10/08/2026 at 04:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Integra LifeSciences stock faces a lower 2026 revenue range of USD 1.634 billion to USD 1.654 billion after the October 2 update. Adjusted EPS guidance is USD 2.30 to USD 2.40, and full operations are targeted for Q2 2027.

IART, US4579852082, Illustration mit AI erstellt.

Integra LifeSciences stock (ISIN US4579852082) is tied to preliminary third-quarter revenue of USD 410 million to USD 412 million after the company updated its 2026 outlook on October 2, 2026. According to GlobeNewswire, flooding at the Cincinnati facility reduced third-quarter revenue by USD 7 million and is expected to affect fourth-quarter revenue by USD 15 million to USD 20 million.

Revenue outlook moves lower

Integra lowered its full-year reported revenue guidance to USD 1.634 billion to USD 1.654 billion from USD 1.654 billion to USD 1.695 billion. The midpoint therefore moved from USD 1.6745 billion to USD 1.644 billion, a reduction of USD 30.5 million.

The company also reduced full-year adjusted earnings per diluted share guidance to USD 2.30 to USD 2.40 from USD 2.40 to USD 2.50. Preliminary adjusted earnings per diluted share for the third quarter are expected at USD 0.55 to USD 0.59, while third-quarter operating cash flow is expected to exceed USD 85 million.

Flood recovery sets the timetable

The Cincinnati site is expected to return to full manufacturing operations during the second quarter of 2027. Integra said insurance recoveries are expected to mitigate a substantial portion of the earnings impact during the recovery period, adding a counterweight to the lower revenue outlook.

The next reporting date is October 21, 2026. According to StockTitan, Integra will release its final third-quarter results before the market opens and hold a conference call at 8:30 a.m. ET.

Analyst target stays above price

According to MarketBeat on October 5, 2026, BMO Capital Markets reduced its price target from USD 18 to USD 15 while maintaining a Market Perform rating. The same report puts the consensus at Reduce across eight analysts, with an average target of USD 17.86, including one Buy, five Hold and two Sell ratings.

IART was trading at USD 13.22 on Nasdaq at 9:45 a.m. ET on October 7, 2026, down 0.75 percent from USD 13.32. The USD 17.86 consensus target was 35.1 percent above that price, while the 52-week range was USD 8.70 to USD 20.49 and market capitalization was USD 1.0 billion.